Status:
UNKNOWN
Lactate Kinetics as a Predictor of Survival in ACLF With Septic Shock
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Acute on Chronic Liver Failure
Eligibility:
All Genders
18-70 years
Brief Summary
Shock is a clinical state of tissue hypoxia. This hypoxia may be brought about by either decreased perfusion or the inability of the cell to extract oxygen in the presence of adequate perfusion. This ...
Detailed Description
• We hypothesise that delta lactate at 6 hours would be a better predictor of survival in patients of ACLF with septic shock when compared to admission lactate Aim and Objective - * Aim: To study th...
Eligibility Criteria
Inclusion
- Patients of Acute on chronic liver failure with septic shock (APASL, Sepsis -3 definitions)
- Age 18-70yrs
- Informed Consent
Exclusion
- Acute coronary syndrome, hemodynamically unstable arrhythmias
- CKD stage 5
- COPD with acute exacerbation
- Acute CVA or Seizures
- Extremely moribund patients
- Hepato-cellular carcinoma (HCC), intrahepatic or extrahepatic malignancy
- Pregnancy
- Diabetic ketoacidosis
Key Trial Info
Start Date :
November 5 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06116305
Start Date
November 5 2023
End Date
August 30 2024
Last Update
November 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences (ILBS)
New Delhi, National Capital Territory of Delhi, India, 110070